This meta-analysis was conducted to compare the efficacy and safety of fulvestrant with aromatase inhibitors in postmenopausal women with hormone receptor-positive (estrogen and/or progesterone receptor positive) advanced breast cancer.
Electronic databases were searched for randomized controlled trials comparing the efficacy and safety of fulvestrant with three aromatase inhibitors (anastrozole/letrozole/exemestane) published through August 31, 2017. Time to progression/progression-free survival was the primary outcome, while overall survival and safety were the secondary outcomes. Time to progression/progression-free survival was evaluated in subgroups determined on age, hormone receptor status, visceral metastasis, and measurable disease. Hazard ratios with 95% confidence intervals were analyzed by STATA 12.0.
Total of seven randomized controlled trials, with 3168 patients were included for analysis. In the overall population, fulvestrant and aromatase inhibitors had similar time to progression/progression-free survival (Hazard ratio 0.93; 95% confidence interval 0.86–1.01, P = 0.102); however, time to progression/progression-free survival for fulvestrant 500 mg was significantly longer compared with aromatase inhibitors (hazard ratio 0.75; 95% confidence interval 0.62–0.91, P = 0.003). Subgroup analysis revealed significant prolongation of time to progression/progression-free survival with fulvestrant compared with aromatase inhibitors in the patients of estrogen and progesterone receptor-positive (hazard ratio 0.86; 95% confidence interval, 0.75–0.98, P = 0.022) and patients aged ≥ 65 years (hazard ratio 0.81; 95% confidence interval 0.68–0.96, P = 0.014). Overall survival was similar in both groups (hazard ratio 0.89; 95% confidence interval 0.70, 1.13, P = 0.334).
In postmenopausal women with estrogen and/or progesterone receptor-positive advanced breast cancer, fulvestrant 500 mg showed better efficacy than aromatase inhibitor, which was not seen with fulvestrant 250 mg. Compared to aromatase inhibitors, fulvestrant prolonged time to progression/progression-free survival in the subgroups including estrogen and progesterone receptor-positive patients and those aged ≥ 65 years.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. https://doi.org/10.3322/caac.20107
Li T, Mello-Thoms C, Brennan PC (2016) Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat 159:395–406. https://doi.org/10.1007/s10549-016-3947-0
Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132. https://doi.org/10.3322/caac.21338
Kümler I, Knoop AS, Jessing CAR et al (2016) Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open 1:e000062. https://doi.org/10.1136/esmoopen-2016-000062
Rugo HS, Rumble RB, Macrae E et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34:3069–3103. https://doi.org/10.1200/JCO.2016.67.1487
Cardoso F, Costa A, Norton L et al (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast Edinb Scotl 23:489–502. https://doi.org/10.1016/j.breast.2014.08.009
Mantas D, Kostakis JD, C. M (2016) Aromatase inhibitors: a comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients. Hell J Surg 88:245–251
Ingle JN (2011) Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids 76:765–767. https://doi.org/10.1016/j.steroids.2011.02.021
Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2–S6. https://doi.org/10.1038/sj.bjc.6601629
Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J Clin Oncol 28:4594–4600. https://doi.org/10.1200/JCO.2010.28.8415
Leo AD, Jerusalem G, Petruzelka L et al (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. JNCI J Natl Cancer Inst 106:djt337–djt337. https://doi.org/10.1093/jnci/djt337
Valachis A, Mauri D, Polyzos NP et al (2010) Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol 73:220–227. https://doi.org/10.1016/j.critrevonc.2009.03.006
Telford C, Jones N, Livings C, Batson S (2016) Network meta-analysis comparing overall survival for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer following failure on prior endocrine therapy. Clin Breast Cancer 16:188–195. https://doi.org/10.1016/j.clbc.2016.02.007
Telford C, Takyar S, Parth J et al (2017) A network meta-analysis of fulvestrant vs alternative first-line endocrine therapies for endocrine therapy-naive postmenopausal hormone receptor-positive advanced or metastatic breast cancer. J Clin Oncol 35:e12545–e12545
Cope S, Ouwens MJNM, Jansen JP, Schmid P (2013) Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health 16:403–417. https://doi.org/10.1016/j.jval.2012.10.019
Bachelot T, McCool R, Duffy S et al (2014) Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 143:125–133. https://doi.org/10.1007/s10549-013-2778-5
Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98:1285–1291. https://doi.org/10.1093/jnci/djj357
Altundag K (2006) Aromatase inhibitors in breast cancer: an overview. Oncologist 11:553–562. https://doi.org/10.1634/theoncologist.11-6-553
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
Higgins JPT, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928–d5928. https://doi.org/10.1136/bmj.d5928
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, Is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403. https://doi.org/10.1200/JCO.2002.10.057
Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial. J Clin Oncol 20:3386–3395. https://doi.org/10.1200/JCO.2002.10.058
Xu B, Jiang Z, Shao Z et al (2011) Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 67:223–230. https://doi.org/10.1007/s00280-010-1483-x
Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14:989–998. https://doi.org/10.1016/S1470-2045(13)70322-X
Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, Advanced Breast Cancer: Results From EFECT. J Clin Oncol 26:1664–1670. https://doi.org/10.1200/JCO.2007.13.5822
Robertson JFR, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST Study. J Clin Oncol 27:4530–4535. https://doi.org/10.1200/JCO.2008.21.1136
Robertson JFR, Bondarenko IM, Trishkina E et al (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388:2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3
Howell A, Robertson JFR, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613. https://doi.org/10.1200/JCO.2004.02.112
Clatot F, Augusto L, Di Fiore F (2017) ESR1 mutations in breast cancer. Aging 9:3–4. https://doi.org/10.18632/aging.101165
Reinert T, Saad ED, Barrios CH, Bines J (2017) Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. Front Oncol https://doi.org/10.3389/fonc.2017.00026
Fribbens C, O’Leary B, Kilburn L et al (2016) Plasma ESR1 mutations and the treatment of estrogen receptor–positive advanced breast cancer. J Clin Oncol 34:2961–2968. https://doi.org/10.1200/JCO.2016.67.3061
Stewart LA, Tierney JF (2002) To IPD or not to IPD?: advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25:76–97. https://doi.org/10.1177/0163278702025001006
Turner NC, Ro J, André F et al (2015) Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 373:209–219. https://doi.org/10.1056/NEJMoa1505270
Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35. https://doi.org/10.1016/S1470-2045(14)71159-3
The authors acknowledge Dr. Priyanka Nair and Karan Sharma from Indegene Pvt. Ltd. for medical writing assistance during the development of this manuscript, as funded by AstraZeneca Pharmaceutical Company Ltd.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Wang, J., Xu, B., Wang, W. et al. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis. Breast Cancer Res Treat 171, 535–544 (2018). https://doi.org/10.1007/s10549-018-4867-y
- Advanced breast cancer
- Hormone receptor
- Aromatase inhibitors